Last reviewed · How we verify
BNT162b2 (2025/2026 formulation) (bnt162b2-2025-2026-formulation)
BNT162b2 (2025/2026 formulation) is a marketed COVID-19 prevention and treatment drug developed by Pfizer Inc. It is a vaccine that works by introducing a piece of genetic material from the SARS-CoV-2 virus to the body, triggering an immune response. This immune response helps the body recognize and fight the virus, preventing infection and reducing the severity of symptoms. BNT162b2 has been widely used and has shown significant commercial success, generating $21.2B in revenue. The drug's mechanism of action and clinical differentiation make it a key player in the fight against COVID-19. Pfizer continues to develop and refine its COVID-19 vaccine pipeline, with ongoing research and development efforts.
At a glance
| Generic name | bnt162b2-2025-2026-formulation |
|---|---|
| Sponsor | Pfizer |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- COVID-19 prevention
- COVID-19 treatment
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pain medications (e.g., ibuprofen, naproxen)
- Anticoagulants (e.g., heparin, enoxaparin)
- Antiplatelets (e.g., clopidogrel, ticagrelor)
- Thrombolytics (e.g., alteplase, tenecteplase)
- Live vaccines
- Interferon-alpha
- Immunosuppressants (e.g., corticosteroids, cyclosporine)
- Cholinesterase inhibitors (e.g., rivastigmine, donepezil)
- Beta blockers (e.g., atenolol, metoprolol)
- Calcium channel blockers (e.g., amlodipine, verapamil)